查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001040

神經調控設備市場：2026-2032年全球市場預測（依設備類型、控制方法、技術、年齡層、治療領域、最終用戶及通路分類）

Neuromodulation Devices Market by Device Type, Control Mechanism, Technology, Age Group, Therapeutic Area, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經調節設備市場價值將達到 54.5 億美元，到 2026 年將成長至 58.5 億美元，到 2032 年將達到 91.3 億美元，複合年成長率為 7.63%。

主要市場統計數據
基準年 2025 54.5億美元
預計年份：2026年 58.5億美元
預測年份 2032 91.3億美元
複合年成長率 (%) 7.63%

我們將著眼於新興臨床應用中的機會和挑戰，為神經調控設備的未來鋪路。

神經調控設備透過向特定神經通路傳遞靶向電刺激或磁刺激，正在革新複雜神經系統疾病、精神疾病和疼痛相關疾病的治療方式。隨著臨床應用從帕金森氏症和慢性疼痛等成熟適應症擴展到重度憂鬱症和癲癇等新興領域，相關人員必須適應快速創新、監管要求不斷變化以及競爭日益激烈的環境。本導言概述了當前產業格局的關鍵趨勢，並為深入分析提供了基礎觀點。

揭示透過突破性創新和不斷變化的患者需求，正在重塑神經調控設備產業的變革性變化。

神經調控設備產業正經歷變革性的轉變，這主要得益於材料科學、數據分析和監管調整的突破性進展。生物相容性電極塗層和節能電池系統的最新進展，使得更小巧、更耐用、更精準的植入式設備得以研發。同時，利用機器學習演算法的軟體創新正在簡化個人化治療通訊協定，從而提高治療反應率並減少不利事件。

分析2025年美國實施的新關稅對供應鏈趨勢和相關人員策略的累積影響。

美國在2025年實施的新關稅為全球神經控制設備供應鏈帶來了重大轉折。對微電極和特殊聚合物等精密零件徵收的進口關稅增加了設備製造商的生產成本。為此，各公司正在重新審視籌資策略，並加強與國內供應商的合作，以減輕這些額外課稅的影響。

關鍵的市場區隔洞察揭示了多樣化的患者人口統計特徵；推動市場發展的技術和最終用戶偏好。

神經調控市場的複雜性源自於其設備形式的多樣性，既有深部腦部刺激器和脊髓刺激設備等侵入性平台，也有經顱直流電刺激和經顱磁刺激等新興的非侵入性治療方法。在侵入性療法中，薦骨神經刺激器刺激器和迷走神經刺激設備為泌尿器官系統和消化器官系統疾病開闢了重要的治療途徑，而深部腦部刺激仍然是運動障礙治療的黃金標準。同時，由於風險較低且門診手術流程簡化，非侵入性技術正不斷拓展其在精神疾病領域的應用。

了解美洲、歐洲、中東和非洲以及亞太地區的區域特徵和戰略成長機會。

在美洲，成熟的保險體系和先進的外科手術基礎設施是其生態系統的特徵。頂尖大學醫院與醫療設備製造商之間進行的前沿合作研究正在加速先進植入式系統的應用。儘管北美地區的健保報銷政策較為嚴格，但一旦獲得可靠的臨床證據，便可獲得清晰的市場准入途徑。因此，各公司正致力於進行長期療效研究，以滿足不同相關人員的需求。

探索引領神經調控設備產業未來的領先製造商的策略和競爭定位。

領先的製造商正採用獨特的策略來鞏固其在神經調控領域的地位。Medtronic正利用其在植入式技術方面的深厚專業知識和全球製造地，拓展其用於治療運動障礙的封閉回路型產品線。與學術機構的合作正在產生重要的長期安全性和有效性數據，從而增強支付方的信心。波士頓科學公司以其在心臟和周邊血管介入領域的強大產品系列而聞名，目前正將其業務多元化拓展至脊髓刺激設備和薦骨神經刺激器，並專注於打造支援遠端監測的整合式數位平台。

為產業領導者提供切實可行的建議，以克服監管複雜性和採用障礙，並加速神經調控領域的創新。

產業領導企業應優先開發閉合迴路調控系統，利用即時數據分析最佳化治療效果。投資於可互通的軟體架構，能夠確保與現有醫院資訊系統和遠端患者監護平台無縫整合。這有助於提高臨床醫生的接受度，並為支付方提供更充分的證據支持。

詳細介紹了嚴謹的調查方法，包括一手訪談、二手資料分析和檢驗，以獲得可靠的市場洞察。

為確保研究結果的有效性和可靠性，本研究採用了綜合調查方法，包括一手資料調查和二手資料調查。首先，作為二手資料調查的一部分，我們對公開的監管文件、同行評審的學術論文、臨床試驗註冊資訊和專利資料庫進行了廣泛的審查。我們有系統地分析了這些資訊來源，以識別關鍵地區的新興技術趨勢、資金籌措模式和不斷變化的報銷框架。

概述新興神經調控設備技術領域中相關人員面臨的策略挑戰和未來發展方向。

總而言之，神經調控設備產業正處於一個關鍵的十字路口，其特點是技術快速創新、監管模式轉變以及相關人員期望不斷變化。閉合迴路療法和非侵入性治療方法的融合正在提高治療的精準度，而新的收費系統和供應鏈重組正在重塑商業策略。能夠有效整合先進分析技術、建立策略夥伴關係並維持供應鏈韌性的公司，將成為產業領導者。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 神經調控設備市場：依設備類型分類

  • 侵入性設備
    • 深部腦部刺激器
    • 薦骨神經刺激器
    • 脊髓刺激設備
    • 迷走神經刺激設備
  • 非侵入式設備
    • 經顱直流電刺激
    • 經顱磁刺激

第9章：依控制方法分類的神經調控設備市場

  • 封閉回路型
  • 開放回路

第10章 神經調控設備市場：依技術分類

  • 電刺激
  • 磁刺激
  • 光遺傳刺激
  • 超音波刺激

第11章：神經調節設備市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第12章：神經調控設備市場：依治療領域分類

  • 消化系統和泌尿系統疾病
  • 神經系統疾病
    • 肌張力不全症
    • 癲癇
    • 帕金森氏症
  • 疼痛管理
    • 慢性疼痛
    • 神經性疼痛
  • 精神疾病
    • 憂鬱症
    • 強迫症

第13章 神經調製設備市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院
  • 研究機構

第14章 神經調製設備市場：依通路分類

  • 離線
  • 線上

第15章 神經調控設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 神經調控設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 神經調控設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國神經調節設備市場

第19章：中國神經調節設備市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • BrainsWay Ltd.
  • ElectroCore, Inc.
  • Integer Holdings Corporation
  • Laborie
  • Life Science Outsourcing, Inc.
  • LivaNova PLC
  • Medtronic plc
  • Neuromod Devices Limited
  • Neuronetics, Inc.
  • Neuropace Inc.
  • NeuroSigma, Inc.
  • Nexstim Oyj
  • Saluda Medical Pty Ltd
  • Soterix Medical Inc.
  • Synapse Biomedical Inc.
  • Synergia Medical SA
  • tVNS Technologies GmbH
Product Code: MRR-205091A88963

The Neuromodulation Devices Market was valued at USD 5.45 billion in 2025 and is projected to grow to USD 5.85 billion in 2026, with a CAGR of 7.63%, reaching USD 9.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.45 billion
Estimated Year [2026] USD 5.85 billion
Forecast Year [2032] USD 9.13 billion
CAGR (%) 7.63%

Setting the Stage for the Future of Neuromodulation Devices by Highlighting Opportunities and Challenges in Emerging Clinical Applications

Neuromodulation devices are revolutionizing the treatment of complex neurological, psychiatric, and pain-related disorders by delivering targeted electrical or magnetic stimuli to specific neural pathways. As clinical applications expand from established indications such as Parkinson's disease and chronic pain into emerging areas like major depressive disorder and epilepsy, stakeholders must adapt to an environment defined by rapid innovation, evolving regulatory requirements, and escalating competition. This introduction outlines the crucial dynamics that underpin the current industry landscape, offering a foundational perspective for deeper analysis.

Firstly, the convergence of advanced hardware miniaturization and sophisticated algorithmic control mechanisms has driven the development of next-generation systems that prioritize safety, efficacy, and patient comfort. As closed loop feedback becomes more prevalent, the ability to monitor and adjust stimulation parameters in real time is setting new standards for therapeutic outcomes. Meanwhile, strategic investments in optogenetic and ultrasonic stimulation technologies are broadening the scope of neuromodulation, offering the potential to treat conditions previously deemed intractable.

Furthermore, the intersection of reimbursements, health economics, and stakeholder collaboration is redefining commercialization strategies. Payers and providers are increasingly demanding robust clinical evidence that demonstrates long-term cost-effectiveness. Consequently, successful market entrants will be those who not only innovate at the technical level but also build integrated value propositions aligned with evolving healthcare ecosystems.

Unraveling the Transformative Shifts Reshaping the Neuromodulation Device Industry through Breakthrough Innovations and Evolving Patient Needs

The neuromodulation device landscape is experiencing transformative shifts driven by breakthroughs in materials science, data analytics, and regulatory adaptation. Recent advances in biocompatible electrode coatings and energy-efficient battery systems have enabled the creation of implantable devices that are smaller, more durable, and capable of delivering precisely calibrated stimulation. At the same time, software innovations powered by machine learning algorithms are streamlining the personalization of therapy protocols, thereby improving response rates and reducing adverse events.

In parallel, the emergence of noninvasive technologies such as transcranial magnetic stimulation and transcranial direct current stimulation is redefining the treatment paradigm by offering outpatient solutions with minimal side effects. These modalities are gaining traction not only in major metropolitan healthcare centers but also in community clinics, where ease of use and patient comfort drive adoption. Regulatory bodies have responded by establishing more flexible frameworks that expedite clinical approvals while maintaining rigorous safety and performance standards.

Additionally, the growing trend toward decentralized clinical trials and real-world evidence collection is reshaping stakeholder expectations around data transparency and long-term outcome measurement. This shift underscores the need for robust post-market surveillance programs and interdisciplinary research collaborations. As a result, manufacturers and clinicians are coalescing around new models of evidence generation that leverage digital health platforms and patient-reported outcome measures to validate therapeutic value continuously.

Analyzing the Cumulative Impact of Newly Implemented United States Tariffs in 2025 on Supply Chain Dynamics and Stakeholder Strategies

The implementation of new United States tariffs in 2025 has introduced a significant inflection point in the global neuromodulation supply chain. Import duties on precision components, including microelectrodes and specialized polymers, have elevated production costs for device manufacturers. In response, companies are reevaluating their sourcing strategies and forging closer partnerships with domestic suppliers to mitigate the impact of these additional levies.

Moreover, the cumulative effect of tariff-related cost pressures is prompting organizations to revisit their pricing models and reimbursement negotiations. As device costs increase, healthcare providers and payers are demanding more comprehensive clinical data to justify higher reimbursement rates. Consequently, companies are accelerating investments in real-world evidence studies that demonstrate long-term cost savings and enhanced patient outcomes.

To address these challenges proactively, several leaders have reshaped their manufacturing footprints, relocating certain production lines to low-cost regions while retaining critical assembly and quality control processes domestically. This hybrid approach balances tariff avoidance with stringent compliance to U.S. regulatory standards. As a result, industry players are pioneering new operational frameworks that blend global efficiency with regional agility, thereby reinforcing supply chain resilience and sustaining market momentum.

Revealing Key Segmentation Insights to Illuminate Diverse Patient Populations Technologies and End User Preferences Driving Market Evolution

Diverse device typologies underpin the neuromodulation market's complexity, with invasive platforms such as deep brain stimulators and spinal cord stimulators coexisting alongside emerging noninvasive modalities including transcranial direct current stimulation and transcranial magnetic stimulation. Within the invasive category, sacral nerve stimulators and vagus nerve stimulators have unlocked critical treatment pathways for urinary and gastrointestinal disorders, whereas deep brain stimulation remains the gold standard for movement disorders. Conversely, noninvasive technologies are extending applications into psychiatric conditions, offering a lower-risk profile and simplified outpatient procedures.

Control mechanisms further differentiate competitive offerings, as closed loop systems integrate continuous neural feedback to adapt stimulation parameters dynamically, enhancing safety and efficacy. Open loop configurations, while established and cost-effective, are now complemented by these next-generation designs that promise higher therapeutic precision. As such, market participants are prioritizing investments in sensor integration and advanced analytics to support automated adjustments based on real-time patient data.

Underlying these mechanical distinctions, a spectrum of stimulation modalities-from electrical and magnetic to optogenetic and ultrasonic-provides a rich array of therapeutic options. Electrical stimulation remains the backbone of most implantable solutions, yet magnetic and ultrasonic techniques are gaining traction due to their noninvasive delivery and potential for finer spatial targeting. Concurrently, optogenetic approaches, still largely in experimental stages, herald a future where genetic modulation can be precisely controlled.

Age group considerations also play a vital role in technology adoption and clinical trial design. While adult and geriatric populations have historically been the primary focus, pediatric use cases are emerging in epilepsy management and certain movement disorders. These developments necessitate device miniaturization and tailored safety protocols to accommodate younger patients.

Disorders spanning neurological, psychiatric, pain management, and gastrointestinal or urological domains illustrate the breadth of therapeutic areas. Neurological conditions such as dystonia, epilepsy, and Parkinson's disease represent core applications, while chronic and neuropathic pain management regimes drive spinal cord stimulator utilization. Psychiatric indications including depression and obsessive-compulsive disorder are increasingly served by both invasive and noninvasive systems, reflecting interdisciplinary collaboration between neurology and psychiatry.

Lastly, end user channels vary from ambulatory surgical centers and high-acuity hospitals to specialized research institutes and outpatient clinics. Distribution pathways blend traditional offline channels with burgeoning online platforms that facilitate telehealth-enabled device monitoring and remote programming. This multi-faceted segmentation underscores the importance of customized strategies that align product features with clinical settings and patient preferences.

Deciphering Regional Nuances and Strategic Growth Opportunities across the Americas Europe Middle East Africa and Asia Pacific Territories

Within the Americas, the ecosystem is characterized by a mature payer environment and high levels of surgical infrastructure. Cutting-edge research collaborations between leading academic medical centers and device manufacturers have accelerated the adoption of advanced implantable systems. Meanwhile, reimbursement policies in North America, though stringent, provide a clear pathway for market entry once robust clinical evidence is secured. Consequently, companies are focusing on longitudinal outcome studies to satisfy diverse stakeholder requirements.

In Europe, the Middle East, and Africa region, heterogenous regulatory frameworks coexist alongside emerging initiatives to harmonize market access protocols. Western Europe continues to adopt noninvasive neuromodulation modalities at a favorable pace, driven by shared-value health economics models. At the same time, Gulf Cooperation Council countries demonstrate strong interest in advanced therapies, incentivizing pilot programs that showcase real-world benefits. Emerging markets in Africa remain nascent but present long-term growth potential as infrastructure investments and healthcare investments climb.

Asia-Pacific exhibits dynamic expansion fueled by government-led healthcare modernization and growing demand for minimally invasive treatments. Japan and Australia spearhead clinical acceptance of both invasive and noninvasive platforms, supported by local manufacturing incentives. In China and India, rapid urbanization and rising healthcare expenditure are catalyzing pilot reimbursement programs, challenging international companies to navigate country-specific regulations and distribution complexities effectively. As such, the region demands agile market entry strategies tailored to each jurisdiction's unique nuances.

Exploring Strategies and Competitive Positioning of Leading Neuromodulation Device Manufacturers Shaping the Industry's Future Trajectory

Leading manufacturers have adopted distinct strategies to fortify their positions within the neuromodulation domain. Medtronic has leveraged its deep expertise in implantable technologies and global manufacturing footprint to expand closed loop offerings for movement disorders. Its collaborations with academic centers have yielded critical long-term safety and efficacy data, enhancing payer confidence. Boston Scientific, known for its robust portfolio in cardiac and peripheral interventions, has diversified into spinal cord stimulators and sacral nerve stimulators, emphasizing integrated digital platforms that support remote monitoring.

Abbott has pursued a complementary approach, repurposing legacy hardware designs into modular systems that accommodate both electrical and ultrasonic stimulation. Its acquisition of smaller innovators has accelerated pipeline development in psychiatric indications, particularly depression. LivaNova, historically focused on epilepsy and vagus nerve stimulation, has deepened its research into optogenetics and next-generation electrode materials, positioning itself at the forefront of minimally invasive therapies. Meanwhile, emerging players such as NeuroPace and Cala Health are gaining traction with novel responsive neurostimulation systems that target refractory epilepsy and essential tremor through personalized algorithms.

Across the ecosystem, strategic partnerships are reshaping competitive dynamics. Collaboration agreements between medical device manufacturers and digital health specialists are enabling seamless integration of cloud-based analytics and patient engagement tools. Joint ventures with contract research organizations facilitate expedited clinical trial execution, while alliances with insurers ensure that real-world evidence is captured to support reimbursement dossiers. This multifaceted approach underscores the importance of adaptability and cross-sector collaboration in sustaining leadership and driving continued innovation.

Empowering Industry Leaders with Actionable Recommendations to Navigate Regulatory Complexities Adoption Barriers and Accelerate Innovation in Neuromodulation

Industry leaders should prioritize the development of closed loop neuromodulation systems that harness real-time data analytics to optimize therapeutic outcomes. By investing in interoperable software architectures, organizations can ensure seamless integration into existing hospital information systems and remote patient monitoring platforms. This will enhance clinician acceptance and strengthen evidence generation for payers.

Simultaneously, companies must forge strategic alliances with research institutes and key opinion leaders to co-design clinical trials that emphasize comparative effectiveness and health economic endpoints. This collaborative model not only accelerates enrollment but also enhances the robustness of data required for reimbursement submissions. Additionally, co-development agreements with digital health providers can facilitate hybrid care models that combine device therapy with telemedicine-enabled follow-up, thereby improving patient adherence and reducing overall care costs.

To mitigate supply chain volatility induced by geopolitical factors, it is advisable to adopt a dual-sourcing strategy for critical components, balancing domestic manufacturing capabilities with selective offshore partnerships. Leaders should also explore the repurposing of existing production lines to accommodate new device formats, thereby reducing capital expenditure. Finally, adopting an agile regulatory engagement framework-leveraging accelerated approval pathways and iterative feedback loops with health authorities-will shorten time to market and reinforce compliance.

By implementing these multifaceted recommendations, stakeholders can navigate complex regulatory and commercial landscapes while maintaining a competitive edge and delivering transformative therapies to patients in need.

Detailing a Rigorous Research Methodology Encompassing Primary Interviews Secondary Data Analysis and Triangulation for Robust Market Insights

This research adopted a comprehensive methodology featuring both primary and secondary research components to ensure the validity and reliability of insights. Initially, secondary research involved an extensive review of publicly available regulatory filings, peer-reviewed journal articles, clinical trial registries, and patent databases. These sources were systematically analyzed to identify emerging technological trends, funding patterns, and evolving reimbursement frameworks across key geographies.

Following this, primary research was conducted through in-depth interviews with over 30 stakeholders, including device manufacturers, leading neurologists, biomedical engineers, and health economic specialists. These interviews provided qualitative context around strategic priorities, operational challenges, and anticipated market developments. Interview findings were then cross-referenced with secondary data to validate conclusions and identify areas of consensus or divergence.

To triangulate data, we employed a multi-dimensional framework that integrated quantitative insights derived from regulatory approvals, clinical trial outcomes, and procurement tender analyses. This approach enabled the identification of consistent patterns and outliers. Rigorous quality checks were performed throughout the research process, including peer reviews and hypothesis validation sessions. By combining these robust methods, the study offers a holistic and actionable perspective on the neuromodulation landscape.

Concluding Reflections on the Strategic Imperatives and Future Directions for Stakeholders Engaging with Emerging Neuromodulation Device Technologies

In summary, the neuromodulation device industry is at a critical juncture defined by rapid technological innovation, shifting regulatory paradigms, and evolving stakeholder expectations. Closed loop and noninvasive modalities are converging to deliver enhanced therapeutic precision, while new tariff structures and supply chain realignments are reshaping operational strategies. Companies that effectively integrate advanced analytics, foster strategic collaborations, and maintain supply chain resilience will emerge as industry frontrunners.

Looking ahead, the pursuit of personalized medicine through optogenetic and ultrasonic stimulation holds the promise of unlocking new clinical applications. However, success will depend on the ability to generate compelling real-world evidence and navigate diverse regional reimbursement frameworks. By aligning technological development with patient-centric care models and interdisciplinary partnerships, stakeholders can capitalize on the transformative potential of neuromodulation to address unmet clinical needs and drive sustainable growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuromodulation Devices Market, by Device Type

  • 8.1. Invasive Devices
    • 8.1.1. Deep Brain Stimulators
    • 8.1.2. Sacral Nerve Stimulators
    • 8.1.3. Spinal Cord Stimulators
    • 8.1.4. Vagus Nerve Stimulators
  • 8.2. Noninvasive Devices
    • 8.2.1. Transcranial Direct Current Stimulation
    • 8.2.2. Transcranial Magnetic Stimulation

9. Neuromodulation Devices Market, by Control Mechanism

  • 9.1. Closed Loop
  • 9.2. Open Loop

10. Neuromodulation Devices Market, by Technology

  • 10.1. Electrical Stimulation
  • 10.2. Magnetic Stimulation
  • 10.3. Optogenetic Stimulation
  • 10.4. Ultrasonic Stimulation

11. Neuromodulation Devices Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Neuromodulation Devices Market, by Therapeutic Area

  • 12.1. Gastrointestinal & Urological Disorders
  • 12.2. Neurological Disorders
    • 12.2.1. Dystonia
    • 12.2.2. Epilepsy
    • 12.2.3. Parkinson's Disease
  • 12.3. Pain Management
    • 12.3.1. Chronic Pain
    • 12.3.2. Neuropathic Pain
  • 12.4. Psychiatric Disorders
    • 12.4.1. Depression
    • 12.4.2. Obsessive-Compulsive Disorder

13. Neuromodulation Devices Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Neuromodulation Devices Market, by Distribution Channel

  • 14.1. Offline
  • 14.2. Online

15. Neuromodulation Devices Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Neuromodulation Devices Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Neuromodulation Devices Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Neuromodulation Devices Market

19. China Neuromodulation Devices Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Aleva Neurotherapeutics SA
  • 20.7. Biotronik SE & Co. KG
  • 20.8. Boston Scientific Corporation
  • 20.9. BrainsWay Ltd.
  • 20.10. ElectroCore, Inc.
  • 20.11. Integer Holdings Corporation
  • 20.12. Laborie
  • 20.13. Life Science Outsourcing, Inc.
  • 20.14. LivaNova PLC
  • 20.15. Medtronic plc
  • 20.16. Neuromod Devices Limited
  • 20.17. Neuronetics, Inc.
  • 20.18. Neuropace Inc.
  • 20.19. NeuroSigma, Inc.
  • 20.20. Nexstim Oyj
  • 20.21. Saluda Medical Pty Ltd
  • 20.22. Soterix Medical Inc.
  • 20.23. Synapse Biomedical Inc.
  • 20.24. Synergia Medical SA
  • 20.25. tVNS Technologies GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROMODULATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROMODULATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA NEUROMODULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. G7 NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 297. NATO NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED